within Pharmacolibrary.Drugs.ATC.J;

model J01FA12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.25,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Rokitamycin is a macrolide antibiotic used for the treatment of respiratory, skin, and soft tissue infections caused by susceptible organisms. It belongs to the 16-membered ring class of macrolides. Rokitamycin was developed and used particularly in Japan and some other countries, but it is not approved by most major regulatory agencies such as FDA or EMA, and is rarely used or available today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetics for average healthy adult after oral administration, as clinical pharmacokinetic studies for rokitamycin are not readily available in published literature.</p><h4>References</h4><ol><li><p>Periti, P, et al., &amp; Novelli, A (1992). Pharmacokinetic drug interactions of macrolides. <i>Clinical pharmacokinetics</i> 23(2) 106–131. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199223020-00004&quot;>10.2165/00003088-199223020-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1511528/&quot;>https://pubmed.ncbi.nlm.nih.gov/1511528</a></p></li><li><p>Nahata, M (1996). Drug interactions with azithromycin and the macrolides: an overview. <i>The Journal of antimicrobial chemotherapy</i> 37 Suppl C 133–142. DOI:<a href=&quot;https://doi.org/10.1093/jac/37.suppl_c.133&quot;>10.1093/jac/37.suppl_c.133</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8818854/&quot;>https://pubmed.ncbi.nlm.nih.gov/8818854</a></p></li><li><p>Cazzola, M, et al., &amp; Rossi, F (1991). Impact of rokitamycin, a new 16-membered macrolide, on serum theophylline. <i>Journal of chemotherapy (Florence, Italy)</i> 3(4) 240–244. DOI:<a href=&quot;https://doi.org/10.1080/1120009x.1991.11739098&quot;>10.1080/1120009x.1991.11739098</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1779258/&quot;>https://pubmed.ncbi.nlm.nih.gov/1779258</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01FA12;
